OR WAIT null SECS
January 09, 2024
The expansion will boost solid-phase peptide synthesis total reactor volume to 32,000 L.
January 05, 2024
MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
January 04, 2024
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
The new Europe headquarters will be the hub for the company’s European operations, including production of product.
January 03, 2024
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
Novel molecular glues are transforming targeted protein degradation.
UK scientists are once again able to participate in the Horizon European research programme thanks to a deal struck in 2023.
January 02, 2024
With the acquisition, AstraZeneca will gain a potential RSV and hMPV combination vaccine.